

COST Action CA17140 Final Conference


Final Program

October 25, 2022

- 13³⁰ – 13⁴⁰ Opening and welcome addresses from the Action Chair
- 13⁴⁰ – 13⁵⁰ Overview of WG1 activity (Tomas Strasak, CZ, WG1 vice-leader)
- 13⁵⁰ – 14²⁰ *Nanoactuators for therapy and diagnosis*, **Jesus M. de la Fuente** (ES, KN1)
- 14²⁰ – 14⁵⁰ *Unlocking the potential of antibody-drug conjugates in oncology: a focus on HER2 signaling pathway*, **Joseph Ciccolini** (FR, KN2)
- 14⁵⁰ – 15¹⁰ *A phthalocyanine-cored dendrimer for photodynamic therapy*, **Jørn B. Christensen** (DK, OCP1)
- 15¹⁰ – 15³⁰ *Evaluation of carbosilane and bis-MPA based dendrimers as anticancer agents*, **Natalia Sanz del Olmo** (SE, OCP2)
- 15³⁰ – 15⁵⁰ *Triggerable nanomedicines for targeted cancer therapy*, **Wafa Al Jamal** (UK, OCP3)
- 15⁵⁰ – 16²⁰ *Ruthenium and copper carbosilane metallodendrimers as anticancer agents*, **Francisco Javier de la Mata** (ES, KN3)
- 16²⁰ – 16³⁰ Coffee break (CB)
- 16³⁰ – 17⁰⁰ *Nanomechanical Phenotype – novel, fast and clinically validated physical biomarker for characterization of cellular and extracellular structures*, **Marko Loparic** (CH, KN4)
- 17⁰⁰ – 17²⁰ *Thiolated liposomes as mucoadhesive oral delivery system*, **Ruth Prassl** (AT, OCP4)
- 17²⁰ – 17⁴⁰ *Optimization of tyrosine kinase inhibitor-loaded gold nanoparticles for triggered antileukemic drug release and cytotoxic evaluation*, **Sanda Boca-Farcau** (RO, OCP5)
- 17⁴⁰ – 18⁰⁰ *Surface modifying PLGA nanoparticles for GBM specific targeting*, **Jason T. Duskey** (IT, OCP6)
- 18⁰⁰ – 18²⁰ *Synthesis and in vitro proof-of-concept studies on nanoparticles (iron oxide/gold) targeting PSMA (Prostate Specific Membrane Antigen) and GRP (Gastrin Releasing Peptide) receptors for PET/MR and SPECT imaging of prostate cancer*, **Christos Liolios** (EL, OCP7)
- 18²⁰ – 18³⁰ Concluding remarks

Evening: social dinner





October 26, 2022

- 9⁰⁰ – 9¹⁰ Overview of WG2 activity (Ivana Vinkovic Vrcek, HR, WG2 leader)
9¹⁰ – 9⁴⁰ *Iron oxide nanoflowers as excellent heating agents for magnetic hyperthermia cancer therapy, **Nguyen Thi Kim Thanh** (UK, KN5)*
9⁴⁰ – 10⁰⁰ *Cancer therapy using porous silicon nanocarriers with stimulus-cleavable linkers, **Nicolas Voelker** (AUS, OCR1)*
10⁰⁰ – 10²⁰ *Biosensors for cancer diagnostics and targeted drug delivery based on DNA aptamers, **Tibor Hianik** (SK, OCR2)*
10²⁰ – 10⁴⁰ *Synthetic glycoconjugates - galectin ligands with a therapeutic potential, **Pavla Bojarova** (CZ, OCR3)*
10⁴⁰ – 11⁰⁰ *Self-assembling ionizable dendrimers for biomedical applications, **Dinesh Dhumal** (FR, OCR4)*

11⁰⁰ – 11¹⁰ CB


- 11¹⁰ – 11⁴⁰ *Beyond nucleic acids as vaccines: curing ocular diseases with nucleic acids?, **Stefaan C. De Smedt** (BE, KN6)*
11⁴⁰ – 12⁰⁰ *Design of novel nanoformulation to decrease cardiotoxicity of doxorubicin, **Krunoslav Ilic** (HR, OCP8)*
12⁰⁰ – 12²⁰ *Carbosilane glycodendrimers for anticancer drug delivery, **Monika Mullerova** (CZ, OCP9)*
12²⁰ – 12⁵⁰ *Nanoparticles for glioblastoma therapy, **Valentin Cena** (ES, KN7)*

12⁵⁰ – 13⁵⁰ Lunch Break

- 13⁵⁰ – 14⁰⁰ Overview of WG3 activity (Carlo V. Catapano, CH, WG3 leader)
14⁰⁰ – 14³⁰ *Multifunctional nanomedicines of chemotherapeutic and antiangiogenic effect to target glioblastoma are validated in 3D tumor microtissue-forming unit and in vivo orthotopic model, **Bruno Sarmiento** (PT, KN8)*
14³⁰ – 14⁵⁰ *Co-clinical organoid platform for individualization of cancer chemotherapy, **Ulf Kahlert** (DE, OCP10)*
14⁵⁰ – 15¹⁰ *NaDeNo – Unleashing the potential of hard-to-deliver drugs, **Yrr Morch** (NO, OCP11)*
15¹⁰ – 15³⁰ *ICG-tagged aptamer as drug delivery system for in vitro and in vivo malignant melanoma models, **Jessica Lopez-Nunez** (PT, OCR5)*

15³⁰ – 15⁴⁰ CB

- 15⁴⁰ – 15⁵⁰ Overview of WG4 activity (Enrico Catalano, IT, WG4 vice-leader)
15⁵⁰ – 16²⁰ *Cryo-EM of drug delivery nano vehicles, **Dganit Danino** (IL, KN9)*



COST ACTION CA 17140
NANO2CLINIC
CANCER NANOMEDICINE - FROM THE
BENCH TO THE BEDSIDE



16²⁰ – 16⁴⁰ *Development of an occupational risk assessment for nanobiomaterials used in advanced therapy medicinal product for cancer treatment, **Virginia Cazzagon** (IT, **OCP12**)*

16⁴⁰ – 17⁰⁰ *Testing extracellular vesicles as cisplatin carriers in lung cancer on a chip platform, **Arturs Abols** (LV, **OCP13**)*

17⁰⁰ – 17²⁰ *A new perspective for cancer prevention using magnetic nanoparticles for the therapy of adiposopathy by magneto-mechanical effect, **Oliviero Gobbo** (IE, **OPC14**)*

17²⁰ – 17⁴⁰ *Potential antitumor application of polyphenol-conjugated turnip mosaic virus-derived nanoparticles, **Corina Lorz** (ES, **OCP15**)*

17⁴⁰ – 18⁰⁰ *Fucoidan/dendrimer nanoparticles for glioblastoma treatment: anti-angiogenic behavior and siRNA delivery studies, **Helena Tomas** (PT, **OCP16**)*

18⁰⁰ – 18³⁰ *Hard road to good manufacturing practices for nanomedicine, **Nazende Gunday Tureli** (DE, **KN10**)*

18³⁰ – 18⁴⁰ Closing and farewell